Cyclophosphamide and Vinorelbine Activate Stem-Like CD8+ T Cells and Improve Anti-PD-1 Efficacy in Triple-Negative Breast Cancer
暂无分享,去创建一个
P. Pelicci | F. Bertolini | A. Raveane | L. Luzi | P. Mancuso | C. Camisaschi | S. Orecchioni | Paolo Falvo | R. Hillje
[1] A. Giacomelli,et al. Circulating endothelial progenitors are increased in COVID‐19 patients and correlate with SARS‐CoV‐2 RNA in severe cases , 2020, Journal of Thrombosis and Haemostasis.
[2] C. Klein,et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy , 2020, Science Translational Medicine.
[3] Insuk Lee,et al. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer , 2020, Genome Medicine.
[4] Thomas D. Wu,et al. Peripheral T cell expansion predicts tumour infiltration and clinical response , 2020, Nature.
[5] P. Fasching,et al. Pembrolizumab for Early Triple-Negative Breast Cancer. , 2020, The New England journal of medicine.
[6] D. Berry,et al. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. , 2020, JAMA oncology.
[7] J. Lee,et al. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. , 2019, JAMA oncology.
[8] Guangyong Peng,et al. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment , 2019, Cellular & Molecular Immunology.
[9] Shannon R. McCurdy,et al. How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide. , 2019, Hematology. American Society of Hematology. Education Program.
[10] A. Kamphorst,et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells , 2019, Nature.
[11] E. Winer,et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.
[12] Shannon R. McCurdy,et al. How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide. , 2019, Blood.
[13] D. Speiser,et al. Intratumoral CD8+ T cells with stem cell–like properties: Implications for cancer immunotherapy , 2019, Science Translational Medicine.
[14] A. Anderson,et al. New Clones on the Block. , 2019, Immunity.
[15] S. Phinn,et al. Australian vegetated coastal ecosystems as global hotspots for climate change mitigation , 2019, Nature Communications.
[16] A. Ribas,et al. Tumour-intrinsic resistance to immune checkpoint blockade , 2019, Nature Reviews Immunology.
[17] R. Weinberg,et al. Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade , 2019, Proceedings of the National Academy of Sciences.
[18] James B. Munro,et al. Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential , 2019, Genome Medicine.
[19] S. Naicker,et al. CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study. , 2019, Blood advances.
[20] Howard Y. Chang,et al. Clonal replacement of tumor-specific T cells following PD-1 blockade , 2019, Nature Medicine.
[21] H. Horlings,et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial , 2019, Nature Medicine.
[22] Pier Giuseppe Pelicci,et al. Cerebro: interactive visualization of scRNA-seq data , 2019, bioRxiv.
[23] M. Wicha,et al. Primary tumor-induced immunity eradicates disseminated tumor cells in syngeneic mouse model , 2019, Nature Communications.
[24] P. Sachs,et al. SMARCAD1 ATPase activity is required to silence endogenous retroviruses in embryonic stem cells , 2019, Nature Communications.
[25] M. Telli,et al. Future of checkpoint blockade in triple-negative breast cancer: combination strategies to lead the way. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] F. Hodi,et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade , 2019, Nature Immunology.
[27] Laurent Gatto,et al. ensembldb: an R package to create and use Ensembl-based annotation resources , 2019, Bioinform..
[28] A. Butte,et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage , 2018, Nature Immunology.
[29] Amy McKee,et al. FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma , 2018, Clinical Cancer Research.
[30] Christoph Hafemeister,et al. Comprehensive integration of single cell data , 2018, bioRxiv.
[31] Mark Gerstein,et al. GENCODE reference annotation for the human and mouse genomes , 2018, Nucleic Acids Res..
[32] P. Carmeliet,et al. Phenotype molding of stromal cells in the lung tumor microenvironment , 2018, Nature Medicine.
[33] Angelica Calleri,et al. Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma , 2018, British Journal of Cancer.
[34] N. Bercovici,et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment , 2018, Proceedings of the National Academy of Sciences.
[35] Paul Hoffman,et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species , 2018, Nature Biotechnology.
[36] Steven J. M. Jones,et al. The Immune Landscape of Cancer , 2018, Immunity.
[37] A. Minn,et al. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. , 2018, Immunity.
[38] J. Taube,et al. PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression , 2018, The Journal of clinical investigation.
[39] F. Bertolini,et al. Adipose Progenitor Cell Secretion of GM-CSF and MMP9 Promotes a Stromal and Immunological Microenvironment That Supports Breast Cancer Progression. , 2017, Cancer research.
[40] Haidong Dong,et al. Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells , 2017, Front. Immunol..
[41] Miles A. Miller,et al. In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy , 2017, Science Translational Medicine.
[42] Andrew D. Rouillard,et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..
[43] R. Weissleder,et al. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. , 2016, Immunity.
[44] J. Mesirov,et al. The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .
[45] L. Zitvogel,et al. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. , 2015, Cancer cell.
[46] D. Waxman,et al. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+ T-cell responses and immune memory , 2015, Oncoimmunology.
[47] M. Hemann,et al. Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy , 2014, Cell.
[48] E. Chen,et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.
[49] H. Matsushima,et al. Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells. , 2009, Cancer research.
[50] D. Koller,et al. The Immunological Genome Project: networks of gene expression in immune cells , 2008, Nature Immunology.
[51] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[52] P. Trail,et al. Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[53] A. Chinnaiyan,et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. , 2018, The Journal of clinical investigation.
[54] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[55] G. Pruneri,et al. The white adipose tissue used in lipotransfer procedures is a rich reservoir of CD34+ progenitors able to promote cancer progression. , 2012, Cancer research.